Diagnosed with Cancer? Your two greatest challenges are understanding cancer and understanding possible side effects from chemo and radiation. Knowledge is Power!
Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Skin Cancer »
- Pembrolizumab/Keytruda helps Melanoma?
Pembrolizumab/Keytruda helps Melanoma?
According to the research linked below, Pembrolizumab/Keytruda helps melanoma patients. Actually, Keytruda is associated with long-term survival for 1 in 5 heavily pretreated melanoma patients. Not a great statistic…
“This real-world cohort of metastatic melanoma patients treated with pembrolizumab demonstrates durable long-term survival in nearly one in five heavily pretreated patients,” study researchers reported…”
I am a long-term survivor of a different incurable cancer. When I read the term “heavily pretreated,” I think of the patient undergoing various types of chemotherapy regimens that probably damaged their gut microbiome.
The second study linked below explains how a diverse, healthy gut microbiome enhances immunotherapy. I’m not an oncologist by any stretch. But in my mind, I wonder how many heavily pretreated melanoma patients had a damaged gut microbiome? And would those heavily pretreated melanoma patients do better with a healthy gut microbiome?
I can’t help but wonder if the health of the gut microbiome is just as important as the immunotherapy, aka Keytruda?
The 5 things you NEED to know for better GUT HEALTH
Now, if you’re a melanoma patient undergoing therapy, you might not be too enthusiastic about eating. My only suggestion is to lean on your caregiver to help you with what Dr. Specter in the video above, says about enhancing your gut health.
If you have any questions, please scroll down the page, post a question or a comment, and I will reply to you ASAP.
Hang in there,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Pembrolizumab Associated With Durable Long-Term Survival in Previously Treated Melanoma
In previously treated patients with melanoma, pembrolizumab therapy is associated with durable long-term survival, according to research published in the European Journal of Cancer…
“This real-world cohort of metastatic melanoma patients treated with pembrolizumab demonstrates durable long-term survival in nearly one in five heavily pretreated patients,” study researchers reported…
The retrospective cohort study included 325 patients with melanoma who had initiated pembrolizumab treatment through the German Expanded Access Program and were treated across 14 eligible skin cancer centers in Germany. Eligible patients had metastatic or nonresectable stage IV melanoma that had progressed on prior therapies, which included ipilimumab, BRAF/MEK inhibition, and chemotherapy…
Gut microbiota shapes cancer immunotherapy responses
Abstract
The gut microbiota significantly influences cancer immunotherapy efficacy by modulating immune responses, remodeling the tumor microenvironment (TME), and producing key metabolites. Strategies such as FMT, probiotics, and dietary interventions show promise in enhancing responses to ICIs and ACTs while reducing immune-related adverse events (irAEs).
This review summarizes clinical and preclinical findings and discusses microbiota-based interventions and future directions for precision immunotherapy…
Conclusion
In summary, the gut microbiota plays a pivotal role in modulating cancer immunotherapy, influencing treatment efficacy, patient response, and therapy-associated toxicity. Recent advances in sequencing technologies and microbiota-targeted interventions, such as FMT, probiotics, and dietary modifications, have opened new avenues for enhancing immunotherapy outcomes.
However, significant challenges remain in translating these findings into clinical practice, primarily due to inter-individual variability and the complexity of host-microbiota interactions.
Future research should focus on integrating multi-omics approaches, AI, and precision medicine to establish causal relationships between microbiota composition and immunotherapy response.
Additionally, exploring the mechanisms by which microbial metabolites influence tumor immune microenvironments will be crucial for developing novel therapeutic strategies. By harnessing the potential of the gut microbiota, clinicians may be able to personalize immunotherapy regimens, improve treatment efficacy, and overcome drug resistance.
Ultimately, continued interdisciplinary research will be essential to fully unlock the clinical potential of microbiota-targeted interventions, paving the way for more effective and individualized cancer treatments.
Pembrolizumab/Keytruda helps melanoma Pembrolizumab/Keytruda helps melanoma